Peptide InjectionsAI
High evidence

Cagrilintide

Peptide therapy: benefits, side effects, cost and protocols

C194H312N54O59S2

4,409 g/mol / CID 171397054
C194H312N54O59S2

Cagrilintide is a long-acting analogue of amylin being tested for obesity and type 2 diabetes treatment, both alone and in combination with semaglutide (CagriSema) for enhanced weight loss efficacy.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
Evidence
Strong Evidence

Who Cagrilintide is usually considered for

  • Appetite regulation
  • Weight management research
  • Glycemic control

How Cagrilintide works

Amylin receptor agonist that may influence satiety signaling, slow gastric emptying, and reduce glucagon secretion.

Key studies

109 papers on PubMed / 66 human trials

  1. 01

    CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

  2. 02

    Verma S, Böttcher M, Brown P et al

    Hypertension / Phase 3

    CagriSema reduced systolic BP by 10.9 mmHg versus 2.8 mmHg with placebo at week 68.

  3. 03

    CagriSema reduced systolic BP by 10.9 mmHg versus 2.8 mmHg with placebo at week 68

  4. 04

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

  5. 05

    Garvey WT, Blüher M, Osorto Contreras CK et al

    N Engl J Med / Phase 3

    Cagrilintide-semaglutide achieved 20.4% weight loss vs 3.0% placebo in adults with overweight/obesity.

  6. 06

    Cagrilintide-semaglutide achieved 20.4% weight loss vs 3.0% placebo in adults with overweight/obesity

  7. 07

    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

  8. 08

    Davies MJ, Bajaj HS, Broholm C et al

    N Engl J Med / Phase 3

    Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% placebo in type 2 diabetes.

  9. 09

    Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% placebo in type 2 diabetes

  10. 10

    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Cagrilintide compound data

C194H312N54O59S2
4409 g/mol
171397054 ↗
20-[[(1S)-4-[[(1S)-5-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(1S)-2-[[(1S,2R)-1-[[(1S)-4-amino-1-[[(1S)-1-[[(1R)-1-[[(1R)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-3-amino-1-[[(1S)-3-amino-1-[[(1S)-2-[[2-[(2S)-2-[[(1S,2S)-1-[[(1R)-1-[(2R)-2-[(2R)-2-[[(1R,2S)-1-[[(1R)-3-amino-1-[[(1R)-1-[[2-[[(1R)-2-[[(1R)-3-amino-1-[[(1R,2S)-1-[(2R)-2-carbamoylpyrrolidine-1-carbonyl]-2-hydroxy-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]-2-methyl-propyl]carbamoyl]-3-oxo-propyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]-3-methyl-butyl]carbamoyl]-2-methyl-butyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-ethyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-oxo-propyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-benzyl-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-4-oxo-butyl]carbamoyl]-2-hydroxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-16-(2-amino-2-oxo-ethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]carbamoyl]pentyl]amino]-1-carboxy-4-oxo-butyl]amino]-20-oxo-icosanoic acid

Cagrilintide questions

What is CAGRILINTIDE?

Cagrilintide is a long-acting amylin analog researched for weight management. It works differently from GLP-1 agonists and is often studied in combination with other peptides.

How does CAGRILINTIDE work?

Amylin receptor agonist that may influence satiety signaling, slow gastric emptying, and reduce glucagon secretion.

Is CAGRILINTIDE legal to buy?

CAGRILINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy CAGRILINTIDE?

CAGRILINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does CAGRILINTIDE belong to?

CAGRILINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of CAGRILINTIDE?

CAGRILINTIDE has been studied for: Appetite regulation, Weight management research, Glycemic control. Amylin analog; often researched in combination protocols.

Cagrilintide in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Cagrilintide?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz